BlueCrest Capital Management’s ADMA Biologics ADMA Stock Holding History

BlueCrest Capital Management’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-23,568	Closed	-$108K	–	1454
2018 Q1	$108K	Buy	+23,568	New	+$93.7K	﹤0.01%	1354

Other funds holding ADMA

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Morgens Waterfall Vintiadis & Co New York $131M AUM 101.21% 1-Year Est. Return

BlueCrest Capital Management's ADMA Position: Q2 2018 in Review

BlueCrest Capital Management sold out of ADMA Biologics (ADMA) in Q2 2018, closing a stake of 23,568 shares — an estimated $108K sold.

BlueCrest Capital Management first reported a position in ADMA in Q1 2018 and held it in 1 quarter. The position peaked at $108K in Q1 2018. 55 funds tracked by Wall St. Rank hold ADMA as of Q2 2018.

BlueCrest Capital Management reported no remaining ADMA Biologics position as of Q2 2018 after selling out during the quarter.
BlueCrest Capital Management sold 23,568 ADMA Biologics shares in Q2 2018, an estimated $108K.
BlueCrest Capital Management first reported a position in ADMA Biologics in Q1 2018 and held it in 1 quarter.
BlueCrest Capital Management's ADMA Biologics position peaked at $108K in Q1 2018.
55 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2018.

Based on BlueCrest Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.